Bain Capital to buy PCI Pharma at $10 billion valuation, Bloomberg News reports

(Reuters) – The capital is in the negotiations, which is given to PCI PHARMA services for contracting drugs, worth $ 10 billion, reports Bloomberg News, citing people familiar with the question.

The purchase firm is in discussions with PCI’s Backers – Kohlberg & Co, Mubadala Investment Co եւ Partners Group Group Group for most Philadelphia services provider reports.

The PCI representative refused to comment.

PCI is a contractor that has supplementary works that include add-on and packaging for pharmacists in sterile sterile conditions. It also provides tools and services that help new drug research and development.

According to the report, Baine has reached a number of potential co-financing, including sovereign wealth funds to finance the deal.

(It reports that Christy Santosh in Bengaluru; editing, Alan Barona)